Core Viewpoint - The company,药捷安康-B (02617.HK), announced its plan to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, which represents approximately 11.33% of the total shares issued as of the announcement date [1] Group 1 - The board of directors has approved the application to the China Securities Regulatory Commission for the conversion of domestic shares into H-shares [1] - The conversion and listing will occur after obtaining all necessary approvals from the China Securities Regulatory Commission and the Stock Exchange of Hong Kong, and complying with all applicable laws and regulations [1] - According to the company's articles of association, there is no need to hold a shareholders' meeting to approve the conversion and listing [1]
药捷安康-B(02617.HK)：建议实行H股全流通